- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04666051
Fibrin Glue in Inguinal Lymphadenectomy
Is There a Role for Fibrin Glue (Sealant) in Seroma Reduction After Inguinal Lymphadenectomy?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Seroma is one of the most frequent complications occurring after ILND as it affects nearly one third of these cases. During the past decades, many actions have been tried in the perioperative care to decrease the incidence of these complications, as employing well vascularized bulky flaps to obliterate the dead space and to protect vessels, great saphenous vein sparing, strict bed rest and fibrin sealant application. Realizing the underlying pathology for seroma formation is the key point in its prevention. Thirty-nine patients scheduled to perform Inguinal lymphadenectomy for various causes have been checked for eligibility to be enrolled in this prospective, randomized study. Thirty-two patients have met the inclusion criteria. Inguinal lymphadenectomy has been performed including scarifying saphenous vein. Sartorius muscle transposition flap was routinely performed for protection of femoral vessels, then an 18 French conventional non-suction tube drain was inserted in all patients. All the previous steps were similar in both groups. At this stage, the wound was closed for the control group, while fibrin glue was prepared to be applied to the fibrin glue group in a dose of 2mL for 100 cm2 surface area. Postoperatively, the daily collected drain fluid was measured till the drain was removed when the daily drainage was less than 30 ml. Then the patients were planned to be followed up postoperatively for at least 4 weeks, to detect the possible clinically encountered complications as seroma, wound infection, or skin flap necrosis.
Patients' demographic data and preexisting co-morbidities were recorded. Operative and pathological data regarding defect size, blood transfusion, primary tumor pathology, and number and status of retrieved lymph nodes were collected. The occurrence of post-operative seroma was the primary outcome. Other non serious adverse effect as hematoma, infection, or skin flap necrosis were recorded and compared between the two groups.
The normality of distribution of variables was verified by Kolmogorov- Smirnov test. Chi-square test (Fisher or Monte Carlo) was used for comparisons between groups for categorical variables. Student t-test was used to compare two groups for normally distributed quantitative variables. For not normally distributed quantitative variables, Mann Whitney test was used to compare between two groups. P value was set to be significant if <0.05.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Patients scheduled to perform ILND for various causes
Exclusion Criteria:
- BMI more than 35,
- Uncompensated diabetes
- Advanced liver disease
- Previous history of surgery and/or irradiation to the inguinal region
- Preoperative chemotherapy
- Significant coagulation disorders
- Platelet counts <100,000/mL.
- Use of systemic steroids or anticoagulants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fibrin glue
A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
|
|
No Intervention: Control
Lymphadenctomy wound was closed after insertion of a drain,
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Seroma Formation
Time Frame: 4 weeks postpertively
|
Collection of serous fluid under the wound flaps. According to the Common Terminology Criteria for Adverse Events (CTCAE) 4.0, Grade 2 and Grade 3 were considered. Grade 2 indicates it is symptomatic; simple aspiration indicated. Grade 3 indicates it is symptomatic, elective radiologic or operative intervention indicated |
4 weeks postpertively
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: M. Ashraf Balbaa, M.D., Menoufia University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4/2015/SURG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seroma
-
Omphis FoundationConsorci Sanitari del MaresmeRecruitingSeroma Following ProcedureSpain
-
Zagazig UniversityCompletedPost-mastectomty SeromaEgypt
-
Anselm TamminenNot yet recruitingSeroma Complicating A Procedure
-
SOMAVAC Medical SolutionsUniversity of TennesseeUnknownHematoma Postoperative | Seroma as Procedural ComplicationUnited States
-
Michigan State UniversityCompletedInfected Seroma After Surgical ProcedureUnited States
-
Severance HospitalCompletedSeroma as Procedural ComplicationKorea, Republic of
-
Ikechukwu Bartholomew UlasiCompleted
-
Hamilton Health Sciences CorporationRecruitingBreast Cancer | Seroma Complicating A Procedure | Hematoma PostoperativeCanada
-
Zuyderland Medisch CentrumNot yet recruiting
-
University of California, San FranciscoDavol Inc.Completed
Clinical Trials on Application of fibrin glue sealant
-
Herlev HospitalCompletedRecurrence | Chronic Pain | Hernia, InguinalDenmark
-
Dr. Praveen B.HNathajirao G. Halgekar Institute of Dental Sciences & Research centre, Karnataka...Completed
-
National Taiwan University HospitalWithdrawn
-
Baxter Healthcare CorporationCompletedBreast Cancer | Lumpectomy | Mastectomy Plus Axillary Lymph Node Dissection | Lymphatic LeakageGermany, Austria, France, Italy
-
Università degli Studi di SassariWHO Collaborating Centre for Epidemiology and Community DentistryCompleted
-
Rijnstate HospitalKimberly-Clark CorporationTerminatedArterial Obstructive DiseasesNetherlands
-
Instituto de Investigación Sanitaria de la Fundación...Completed
-
Seoul National University HospitalKorea Health Industry Development InstituteActive, not recruitingLateral EpicondylitisKorea, Republic of
-
Ondokuz Mayıs UniversityCompleted